View ValuationCHAPTERS Group 향후 성장Future 기준 점검 5/6CHAPTERS Group (는) 각각 연간 86.5% 및 31.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 94.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 5.2% 로 예상됩니다.핵심 정보86.5%이익 성장률94.06%EPS 성장률Diversified Financial 이익 성장59.3%매출 성장률31.4%향후 자기자본이익률5.19%애널리스트 커버리지Low마지막 업데이트07 May 2026최근 향후 성장 업데이트Price Target Changed • May 20Price target decreased by 8.2% to €45.00Down from €49.00, the current price target is an average from 2 analysts. New target price is 47% above last closing price of €30.60. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €0.69 next year compared to a net loss per share of €0.50 last year.모든 업데이트 보기Recent updatesPrice Target Changed • May 20Price target decreased by 8.2% to €45.00Down from €49.00, the current price target is an average from 2 analysts. New target price is 47% above last closing price of €30.60. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €0.69 next year compared to a net loss per share of €0.50 last year.공시 • Jun 02CHAPTERS Group AG, Annual General Meeting, Jul 09, 2025CHAPTERS Group AG, Annual General Meeting, Jul 09, 2025, at 14:00 W. Europe Standard Time.공시 • May 23Expatrio Global Services GmbH agreed to acquire Fintiba GmbH from CHAPTERS Group AG (XTRA:CHG).Expatrio Global Services GmbH agreed to acquire Fintiba GmbH from CHAPTERS Group AG (XTRA:CHG) on May 22, 2025. Bastian Krieghoff, CEO of Fintiba, will be appointed to the Executive Board of CHAPTERS Group AG by the Supervisory Board. The transaction is subject to the usual contractual conditions is expected to close in May 2025.Reported Earnings • Oct 22First half 2024 earnings released: €0.23 loss per share (vs €0.18 loss in 1H 2023)First half 2024 results: €0.23 loss per share (further deteriorated from €0.18 loss in 1H 2023). Revenue: €50.0m (up 49% from 1H 2023). Net loss: €4.48m (loss widened 49% from 1H 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Diversified Financial industry in Germany. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 40% per year, which means it is well ahead of earnings.공시 • Oct 18CHAPTERS Group AG (XTRA:CHG) acquired Xplain AG.CHAPTERS Group AG (XTRA:CHG) acquired Xplain AG on October 18, 2024. Xplain includes the two companies Xplain AG and the Spanish development partner Xplain Ibérica. Both will continue to operate independently, as Andreas Löwinger, CEO of Xplain AG, told the Keystone-SDA news agency. The total of 60 employees of both companies will keep their jobs. All projects will also be continued. Löwinger will remain CEO until a successor is found. CHAPTERS Group AG (XTRA:CHG) completed the acquisition of Xplain AG on October 18, 2024.New Risk • Jun 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).공시 • Jun 05CHAPTERS Group AG, Annual General Meeting, Jul 09, 2024CHAPTERS Group AG, Annual General Meeting, Jul 09, 2024, at 14:00 W. Europe Standard Time.Reported Earnings • May 28Full year 2023 earnings releasedFull year 2023 results: Revenue: €78.3m (up 86% from FY 2022). Net loss: €4.08m (loss narrowed 38% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe.New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).New Risk • Nov 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.3% average weekly change). Minor Risk Shareholders have been diluted in the past year (10.0% increase in shares outstanding).Reported Earnings • Oct 05First half 2023 earnings released: €0.25 loss per share (vs €0.035 profit in 1H 2022)First half 2023 results: €0.25 loss per share (down from €0.035 profit in 1H 2022). Revenue: €33.7m (up 77% from 1H 2022). Net loss: €4.20m (down €4.72m from profit in 1H 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 49% per year whereas the company’s share price has increased by 45% per year.New Risk • Oct 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding).New Risk • Sep 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.Reported Earnings • May 30Full year 2021 earnings released: €0.21 loss per share (vs €0.68 loss in FY 2020)Full year 2021 results: €0.21 loss per share (up from €0.68 loss in FY 2020). Revenue: €28.7m (up €27.6m from FY 2020). Net loss: €2.27m (flat on FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 111 percentage points per year, which is a significant difference in performance.Reported Earnings • Sep 22First half 2021 earnings releasedFirst half 2021 results: Net income: €15.7k (up €29.8k from 1H 2020).Reported Earnings • Jun 29Full year 2020 earnings releasedFull year 2020 results: Net loss: €2.27m (loss narrowed 55% from FY 2019).Is New 90 Day High Low • Feb 12New 90-day high: €5.55The company is up 17% from its price of €4.76 on 13 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 5.0% over the same period.Is New 90 Day High Low • Jan 27New 90-day low: €4.24The company is down 9.0% from its price of €4.68 on 28 October 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 11% over the same period.Is New 90 Day High Low • Dec 18New 90-day low: €4.40The company is down 9.0% from its price of €4.84 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is flat over the same period.Is New 90 Day High Low • Oct 01New 90-day low: €4.76The company is down 16% from its price of €5.70 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 9.0% over the same period.이익 및 매출 성장 예측DB:CHG - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20284886N/AN/A112/31/202730856283212/31/2026219-44662212/31/2025158-16102916/30/2025132-231418N/A3/31/2025121-171015N/A12/31/2024111-11711N/A9/30/202499-9711N/A6/30/202487-6711N/A3/31/202479-559N/A12/31/202371-447N/A9/30/202364-758N/A6/30/202357-958N/A3/31/202349-847N/A12/31/202242-646N/A9/30/202245-456N/A6/30/202248-257N/A3/31/202238-245N/A12/31/202129-223N/A9/30/202114-2N/AN/AN/A6/30/20210-2N/AN/AN/A3/31/20211-2N/AN/AN/A12/31/20201-2N/AN/AN/A9/30/20201-4N/AN/AN/A6/30/20201-5N/AN/AN/A3/31/20201-5N/AN/AN/A12/31/20190-5N/AN/AN/A9/30/201911N/AN/AN/A6/30/201918N/AN/AN/A3/31/201928N/AN/AN/A12/31/201838N/AN/AN/A9/30/201834N/AN/AN/A6/30/201830N/AN/AN/A3/31/201830N/AN/AN/A12/31/201731N/AN/AN/A9/30/201730N/AN/AN/A6/30/201730N/AN/AN/A3/31/201730N/AN/AN/A12/31/201630N/AN/AN/A9/30/201630N/AN/AN/A6/30/201630N/AN/AN/A3/31/201630N/AN/AN/A12/31/201530N/AN/AN/A9/30/201530N/AN/AN/A6/30/201531N/AN/AN/A더 보기애널리스트 향후 성장 전망수입 대 저축률: CHG 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(1.9%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: CHG (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: CHG 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: CHG 의 수익(연간 31.4%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: CHG 의 수익(연간 31.4%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: CHG의 자본 수익률은 3년 후 5.2%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YDiversified-financials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 15:48종가2026/05/26 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스CHAPTERS Group AG는 2명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Andreas WolfBerenbergAlexander Zienkowiczmwb research AG
Price Target Changed • May 20Price target decreased by 8.2% to €45.00Down from €49.00, the current price target is an average from 2 analysts. New target price is 47% above last closing price of €30.60. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €0.69 next year compared to a net loss per share of €0.50 last year.
Price Target Changed • May 20Price target decreased by 8.2% to €45.00Down from €49.00, the current price target is an average from 2 analysts. New target price is 47% above last closing price of €30.60. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €0.69 next year compared to a net loss per share of €0.50 last year.
공시 • Jun 02CHAPTERS Group AG, Annual General Meeting, Jul 09, 2025CHAPTERS Group AG, Annual General Meeting, Jul 09, 2025, at 14:00 W. Europe Standard Time.
공시 • May 23Expatrio Global Services GmbH agreed to acquire Fintiba GmbH from CHAPTERS Group AG (XTRA:CHG).Expatrio Global Services GmbH agreed to acquire Fintiba GmbH from CHAPTERS Group AG (XTRA:CHG) on May 22, 2025. Bastian Krieghoff, CEO of Fintiba, will be appointed to the Executive Board of CHAPTERS Group AG by the Supervisory Board. The transaction is subject to the usual contractual conditions is expected to close in May 2025.
Reported Earnings • Oct 22First half 2024 earnings released: €0.23 loss per share (vs €0.18 loss in 1H 2023)First half 2024 results: €0.23 loss per share (further deteriorated from €0.18 loss in 1H 2023). Revenue: €50.0m (up 49% from 1H 2023). Net loss: €4.48m (loss widened 49% from 1H 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Diversified Financial industry in Germany. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 40% per year, which means it is well ahead of earnings.
공시 • Oct 18CHAPTERS Group AG (XTRA:CHG) acquired Xplain AG.CHAPTERS Group AG (XTRA:CHG) acquired Xplain AG on October 18, 2024. Xplain includes the two companies Xplain AG and the Spanish development partner Xplain Ibérica. Both will continue to operate independently, as Andreas Löwinger, CEO of Xplain AG, told the Keystone-SDA news agency. The total of 60 employees of both companies will keep their jobs. All projects will also be continued. Löwinger will remain CEO until a successor is found. CHAPTERS Group AG (XTRA:CHG) completed the acquisition of Xplain AG on October 18, 2024.
New Risk • Jun 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).
공시 • Jun 05CHAPTERS Group AG, Annual General Meeting, Jul 09, 2024CHAPTERS Group AG, Annual General Meeting, Jul 09, 2024, at 14:00 W. Europe Standard Time.
Reported Earnings • May 28Full year 2023 earnings releasedFull year 2023 results: Revenue: €78.3m (up 86% from FY 2022). Net loss: €4.08m (loss narrowed 38% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe.
New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).
New Risk • Nov 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.3% average weekly change). Minor Risk Shareholders have been diluted in the past year (10.0% increase in shares outstanding).
Reported Earnings • Oct 05First half 2023 earnings released: €0.25 loss per share (vs €0.035 profit in 1H 2022)First half 2023 results: €0.25 loss per share (down from €0.035 profit in 1H 2022). Revenue: €33.7m (up 77% from 1H 2022). Net loss: €4.20m (down €4.72m from profit in 1H 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 49% per year whereas the company’s share price has increased by 45% per year.
New Risk • Oct 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding).
New Risk • Sep 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.
Reported Earnings • May 30Full year 2021 earnings released: €0.21 loss per share (vs €0.68 loss in FY 2020)Full year 2021 results: €0.21 loss per share (up from €0.68 loss in FY 2020). Revenue: €28.7m (up €27.6m from FY 2020). Net loss: €2.27m (flat on FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 111 percentage points per year, which is a significant difference in performance.
Reported Earnings • Sep 22First half 2021 earnings releasedFirst half 2021 results: Net income: €15.7k (up €29.8k from 1H 2020).
Reported Earnings • Jun 29Full year 2020 earnings releasedFull year 2020 results: Net loss: €2.27m (loss narrowed 55% from FY 2019).
Is New 90 Day High Low • Feb 12New 90-day high: €5.55The company is up 17% from its price of €4.76 on 13 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 5.0% over the same period.
Is New 90 Day High Low • Jan 27New 90-day low: €4.24The company is down 9.0% from its price of €4.68 on 28 October 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 11% over the same period.
Is New 90 Day High Low • Dec 18New 90-day low: €4.40The company is down 9.0% from its price of €4.84 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is flat over the same period.
Is New 90 Day High Low • Oct 01New 90-day low: €4.76The company is down 16% from its price of €5.70 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 9.0% over the same period.